Announcements and the record of the programme as it is built.
Twelve months of the Pakistan National Genome Programme.
A year ago the Pakistan National Genome Programme was a concept and a conviction. A country of more than 240 million people, with one of the highest rates of consanguinity in the world, should not be nearly absent from human genetics. The way to change that was not another exported dataset. It was a programme the State would own.
In the twelve months since, on the founders' own capital and across five jurisdictions, the LydiaRx team has taken that concept to an unsolicited proposal for one million whole genomes, submitted to the Government of Pakistan under its Public Procurement Rules; to concession-grade programme agreements, a locally majority-owned national joint venture and a data-sovereignty and licence framework, drafted and in negotiation; to three United States provisional patent applications covering Atlas, Phylax and Prism, the platform layer that makes sovereignty enforceable rather than promised; and to an independent Governance and Ethics Board chaired by the former Chief Executive of Our Future Health, with Pakistan-resident clinical and academic co-leads.
None of it was linear. We spoke with ministers and secretaries, state counsel, laboratory principals, supplier executives, geneticists and ethicists. Every conversation tested whether we understood the country, the science and the structure well enough to be trusted with the next step. More than once the answer changed the design. The demonstration pilot is smaller and more rigorous than the one we first drew. The consent model is tiered and runs in Urdu and the regional languages. The reference asset Pakistan will build is a pangenome. It uses its own population's haplotypes, not a European scaffold with Pakistani variation forced onto it. It will be released open-access from Pakistani soil. No output is commercialised before the government agreement is signed. Every discovery from the pilot is royalty-free to Pakistan's health system.
What we learned is simple to state and difficult to do. Sovereignty is not a clause; it is an architecture, and it has to be enforced at the platform layer where an auditor can see it. Governance is not a committee; it is an institution, nationally led, that decides every use of the data and publishes what it finds. And a national genome programme is not a sequencing contract. It is national infrastructure, and it has to be built like one.
What comes next is the pilot itself. 400 whole genomes at 30× long-read coverage over six to nine months. Ethics approval before the first participant is approached. Independent audits published at months three and nine. The first Pakistani pangenome at the end of it. It is sized to prove the platform, the consent model and the reference method before scale. It will be the reference standard for every programme that follows.
A national programme for Pakistan. LydiaRx announces its role as structuring and technical partner for a one-million-genome national programme in Pakistan.
Dr Shahid Hanif joins as adviser. Formerly Head of Health Data and Outcomes at the ABPI; now Managing Director of the GetReal Institute.
Start with a briefing. It commits you to nothing.